About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Method to Treat Acute Myeloid Leukemia with CAR T Cells Identified

by Thilaka Ravi on June 3, 2018 at 2:31 PM
Font : A-A+

New Method to Treat Acute Myeloid Leukemia with CAR T Cells Identified

A new path towards treating Acute Myeloid Leukemia (AML) with CAR T cells may emerge from a new approach pioneered at the University of Pennsylvania's Abramson Cancer Center.

To treat AML, investigators have to target a specific protein - CD33 - that is also expressed on healthy cells, meaning the therapy cannot attack the cancer without causing other serious damage to the residual normal bone marrow.

Advertisement


The new method uses the gene editing tool CRISPR/Cas9 to remove CD33 from healthy blood-forming stem cells, leaving the cancerous cells as the only targets left for the CD33 hunter cells to attack. Penn researchers and their collaborators at the National Institutes of Health published their proof-of-concept findings in Cell.

AML is the second most common type of leukemia, and the American Cancer Society estimates there will be almost 20,000 new cases in the United States this year. Many of these patients will undergo a bone marrow transplant. To treat a related leukemia called acute lymphoid leukemia (ALL), investigators at Penn previously developed CAR T cell therapy, which involves collecting patients' own immune T cells, reprogramming them to kill cancer, and then infusing them back into patients' bodies.
Advertisement

Currently, both CAR T cell therapies approved for use by the U.S. Food and Drug Administration target cells that express a protein called CD19, for ALL and non-Hodgkin's lymphoma. However, this is not an effective target for AML, since AML does not express CD19. Researchers have therefore been looking for other potential cellular targets.

One promising example is a protein known as CD33, but previous attempts to target CD33 have proven damaging to healthy cells. While damage to healthy cells could be prevented by making the CART cells short-lasting, this would defeat the purpose of one of CAR T's greatest strengths - their ability to last for years, circulate in the body, and protect the patient from relapse.

"This therapy is meant to be a true living drug, and we know that CAR T cells can live on in patients' bodies for years after infusion, so turning them off would be self-defeating," said the study's co-senior author Saar I. Gill, MD, PhD, an assistant professor of Hematology-Oncology at Penn. Cynthia E. Dunbar, MD, a senior investigator at the National Heart, Lung, and Blood Institute, is a co-senior author. The co-first authors are Miriam Yunhee Kim, MD, then a post-doctoral researcher in Gill's lab, and Kyung-Rok Yu PhD, a post-doctoral fellow under Dunbar.

"This study represents a significant advance toward effective and safe targeting of leukemia cells using CAR T cells," Dunbar said. "A key to this advance is the use of next-generation gene-editing technology to achieve this type of antigen-specific immunotherapy, even when the target is also present on normal bone marrow cells."

Since the hunter cells are unable to distinguish between normal and malignant cells, the researchers developed an innovative approach to genetically engineer the normal stem cells so they no longer resemble the leukemia. They used the CRISPR/Cas9 gene editing tool to remove CD33 from healthy cells. To their surprise, healthy stem cells lacking CD33 functioned normally. This resulted in the CD33 protein now being unique to the leukemia cells, leaving the CAR T cells free to attack.

"None of the existing CAR T approaches target a cancer-specific antigen - other than EGFRvIII in brain cancer - but with this approach, we can create a cancer-specific antigen, which allows us to unleash CAR T cells to their maximal capacity," Gill said.

Gill and his team have already put this concept into practice and have shown it to be effective in mouse and monkey models. They've also demonstrated its effect on human cells in a laboratory setting.

"Think of this as bone marrow transplant 2.0; the next generation of transplants," Gill said. "It gives you a super powerful anti-leukemia effect thanks to the CAR T cells, but at the same time it has the potential to get rid of the main toxicity."

Their next step is to move this approach into human trials at Penn.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Leukemia Parkinsons Disease Surgical Treatment Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Multiple Myeloma Diet and Nutrition for Healthy Weight Loss Diabetes Type 2 and Its Link to Sugar-Sweetened Beverages Bone Marrow Transplantation Hairy Cell Leukemia 

Recommended Reading
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving ......
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by .....
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Bone Marrow Transplantation
Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are .....
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lympho...
Diabetes Type 2 and Its Link to Sugar-Sweetened Beverages
Sugar-sweetened beverages contribute to metabolic syndrome leading to higher risk for type-2 diabete...
Diet and Nutrition for Healthy Weight Loss
Correct diet and a planned exercise regime is the mantra of healthy and sustainable weight loss....
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a type of leukemia where there are increased numbers of abnormal B-lymp...
Multiple Myeloma
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Meh...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use